Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection

Hye Won Lee, Seung Up Kim, Oidov Baatarkhuu, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang Hyub Han, Beom Kyung Kim

Research output: Contribution to journalShort survey

3 Citations (Scopus)

Abstract

Nucleos(t)ide analogs (NUCs) are recommended when both are fulfilled in the absence of hepatocellular carcinoma (HCC) or cirrhosis; (1) elevated serum hepatitis B virus (HBV)-DNA (≥20,000 IU/mL for hepatitis B e antigen–positive chronic hepatitis B [CHB] or ≥2000 IU/mL for hepatitis B e antigen–negative CHB) and (2) serum alanine aminotransferase ≥2× upper limit of normal.1 Therefore, many patients still remain untreated. Such untreated patients have so called “minimally active CHB,” where serum HBV-DNA is persistently >2000 IU/mL and other parameters for NUCs are below the criteria.2 There have been little data concerning their prognosis.

Original languageEnglish
Pages (from-to)2808-2810.e2
JournalClinical Gastroenterology and Hepatology
Volume17
Issue number13
DOIs
Publication statusPublished - 2019 Dec

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection'. Together they form a unique fingerprint.

  • Cite this